NEW YORK (GenomeWeb News) – Sequenom reported after the close of the market Thursday that its first-quarter revenues grew 10 percent year over year, driven by a sharp uptick in diagnostic services that was somewhat offset by a decline in genetic analysis product sales and services.

The San Diego-based molecular diagnostics firm brought in total revenues of $14.9 million for the three-month period ended March 31, compared to $13.5 million for the first quarter of 2011. It fell short of Wall Street's consensus estimate of $16.3 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers test gene therapy targeting a different cancer protein in a new trial, the New York Times reports.

Pennsylvania State University researchers found that salivary microRNAs could predict which kids would have longer concussion symptoms, according to NPR.

The Associated Press reports Alex Azar, the new Department of Health and Human Services secretary nominee, made millions of dollars as a pharmaceutical executive.

In PNAS this week: immune profiling of breast cancer, transposable element patterns in rice, and more.